Reports
Prohibition Partners provides reliable and credible data on commercial opportunities, market sizes and the regulatory environment in key cannabis markets.
Download our reports
Latest Release
The European Cannabis Report: 6th Edition
This report takes an in-depth look at the progress of cannabis legalisation across Europe, the trade flows on the continent, the business opportunities, the medical products on the market and the patients who use them. We also consider how COVID-19 has affected the market in Europe and what this means for the year ahead.
2020 was a huge year for cannabis in Europe and around the globe. The fourth quarter of 2020 in particular saw several important developments. In November, the European Court of Justice ruled that CBD is not to be considered a narcotic substance under EU Law. Weeks later, the UN finally recognised the medical potential of cannabis by removing the plant and its derivatives from Schedule IV of the Single Convention on Narcotic Drugs.
We estimate that over 60,000 people were able to access cannabis medications for the first time in Europe during 2020, bringing the total to 185,000 patients accessing medical cannabis treatment in the region during the year. Overall, we estimate the value of the market for medical cannabis to be worth €230.7 million as of the end of 2020. Further, we expect the value of European cannabis to grow with a CAGR of 67.4%, to reach €3.2 billion in 2025. Our approach to forecasting the European cannabis industry has its foundation in the database of historical data points (sales, patients, volumes, imports, prices etc.), available in Atalis.
As the patient access to medical cannabis advances across Europe, so too do the opportunities for businesses to embed themselves in niches of the value chain, before the market becomes more established. The European Cannabis Report: Sixth Edition is designed to support businesses in doing so, along with the conferences offered by Prohibition Partners Live as well as our Consulting services for cannabis and psychedelic ventures.
The European Cannabis Report: 6th Edition examines:
- The European cannabis market will be worth €403.4 million by the end of 2021. We expect the market to grow with a CAGR of 67.4% from 2021 to reach €3.2 billion by 2025.
- By the end of the forecast period, we expect several nations to introduce legal access to adult-use cannabis including Netherlands, Switzerland, Germany and others. We estimate these sales could be worth over €500 million by 2025.
- We predict Germany will constitute over half of the European market until 2024 and will be worth over €840 million by the end of the forecast period. By 2025, large countries like France and the UK will have developed their patient access considerably and will represent a significant share of the European market.
In collaboration with:
Download our reports
The Impact Series: Disrupting Petcare
Disrupting Petcare provides an overview of some of the key developments taking place in the emerging CBD pet supplement market. It explores the regulatory developments occurring in key markets, and looks into how much the market could be worth in the coming years.
In addition, the report examines the latest CBD pet supplement product development and innovation, highlighting the activity of some of the world’s biggest hemp petcare companies. The report focuses on the development of cannabis petcare products available for pet wellness use, rather than via a medical prescription, and includes CBD products that have been made from hemp. The scope of the report refers only to those packaged petcare goods that can be purchased legally.
Due to the perceived and documented positive health and wellness effects attributed to cannabis and CBD in recent years, new markets are starting to emerge and flourish. Demand is rising for innovative consumer packaged goods (CPG) which include cannabis-based ingredients, such as hemp or CBD. There is strong growth in the innovation of CBD and hemp-based products specifically designed for pets.
The Impact Series: Disrupting Petcare examines:
- Prohibition Partners projects global sales of CBD petcare products to reach US$424.4 million by 2024, representing a compound annual growth rate (CAGR) of 18.6%.
- The North American market currently has
the highest rate of pet CBD purchasers and returners with 22% of pet owners having already bought CBD products in the last 12 months. -
Over half (64%) of pet CBD purchasers are in the 25-35 and 35-44 age brackets.
Download our reports
The North American Cannabis Report: Second Edition
In 2020, the US saw further states legalising adult-use cannabis, Canada rolling out innovative Cannabis 2.0 products and COVID-19 accelerating North American sales of adult-use cannabis products. As 2021 commences and the North American cannabis industry continues to show promising developments, Prohibition Partners launches The North American Cannabis Report: Second Edition which provides a deep-dive on the current state of the cannabis industry in the US and Canada.
The report provides a deep-dive assessment of the current social, political, economic and legal changes in the North American Cannabis Industry. The report examines the 2020 US election outcomes, the US Vape Crises, Social Equity Programmes, the Canadian Cannabis 2.0 roll-out and COVID-19. now available both in digital and print versions for purchase.
North American legal sales of cannabis are estimated to reach US$39.1 billion by 2025, with adult-use cannabis sales reflecting a growth rate of 144% between 2020 and 2025. The projected number is primarily fuelled by the introduction of US states legalising adult-use cannabis sales, product innovation in the Cannabis 2.0 segment and the increase of North American cannabis consumption.
The North American Cannabis Report: Second Edition examines:
- Estimated sales of legal cannabis are expected to reach US$39.1 billion by 2025, reflecting a 144% growth between 2020 and 2025.
- US adult-use cannabis users are expected to grow from 8.2 million in 2020 to 23.9 million by 2025.
- Yearly US consumption of cannabis is predicted to grow from 982,349 KG to 3,008,535 by 2025.
In collaboration with:
Download our reports
Germany: Cannabis & CBD Consumer Report
Germany is set to become one of the largest single markets for cannabis and CBD anywhere in the world. Despite the fact that millions of Germans are using CBD and cannabis, relatively little is currently known about these consumers. In this report we highlight the topics which are most pressing for patients and consumers and should be of significant value to anyone wishing to meet the growing demand for these products in the country.
The report also aims to examine legislation surrounding over-the-counter and prescription drug formats in Germany, mapping the routes to patients and consumers. Germany: Cannabis and CBD Consumer Report is now available both in digital and print versions for purchase.
Germany: Cannabis and CBD Consumer Report, produced by Prohibition Partners, is part of our consumer series where we conduct in-depth quantitative consumer research to provide a deeper understanding of consumer usage, purchase and attitudes in the cannabis, CBD and infused consumer goods markets. We surveyed over 26,000 adults aged 16+, with participants selected based on set quotas of gender and age to ensure that survey samples are proportionally representative of the respective populations.
Germany: Cannabis & CBD Consumer Report examines:
- While the users of CBD and cannabis for medicinal purposes are distinct populations, they both have large populations of elder consumers whereas recreational cannabis is dominated by those under the age of 40.
- The patients and users of CBD, and cannabis for medical and recreational purposes form clearly distinct groups in demographics, geographics and consumptions habits. Over 75% of consumers make purchases in just one of these three categories rather than a combination.
- While slightly more men than women purchase cannabis and CBD in Germany, analysis of frequent users show that CBD consumption is heavily dominated by self-declaring females, with men making up 62 and 56% of cannabis for recreational and medical purposes respectively.
Download our reports
The Latin America and Caribbean Cannabis Report: Second Edition
Cannabis has been present in Latin American countries for centuries. The Latin America and Caribbean Cannabis Report investigates pioneering legalisation from Colombia and Uruguay, joined in some degree by Argentina, Brazil, Chile, Ecuador, Paraguay, Peru, Jamaica, Trinidad and Tobago, and St Kitts. They are all following the path of decriminalisation and with many taking steps towards full legalisation.
There are high hopes for this region, with unmatched cost-benefit possibilities, a strategic location and an internal market that could lead to high demand from a population expected to surpass the 700 million mark during the current decade. LAC also benefits from low-cost labour and construction costs, meaning that the overall cost of production can be up to 80% lower than that of North America.
Growing cannabis in LAC is therefore a high-yield and high-margin package, and the region is fast recognising its own potential to become a major player in the hemp and cannabis industry worldwide. Our deep-dive into this area investigates the reasons behind the regions newly developed growth analysing legislation, production, innovation, the market and much more.
The Latin America and Caribbean Cannabis Report: Second Edition examines:
- Total trade between Latin American countries and China has increased from US$17 billion in 2002 to over US$315 billion in 2019.
- A gram of cannabis bud is worth between US$0.5 and US$0.8 in Colombia, whereas in Canada the same amount can cost US$2.14.
- The LAC cannabis industry, has an estimated market value 2020: US$168 million which looks set to grow to US$824 million by 2024.
In collaboration with:
Download our reports
CBD – A Supply Overview
CBD is a vast and complex subject area that touches on all aspects of the cannabis market – medical, pharmaceutical, recreational and packaged consumer products. Within this report, CBD – A Supply Overview, Prohibition Partners examines legislation, cultivation, extraction, production, finance and retail across the global CBD industry. Moving away from the fragmented structure that has characterised the industry, we document the rise of vertical integration and the emergence of regulation.
Our deep-dive into this exciting opportunity addresses many of the barriers that are preventing the industry from achieving its full potential and highlights those trends and developments that are driving the market forward.
CBD – A Supply Overview examines:
- Europe currently plants 40,000 hectares of hemp each year and this is expected to grow to 100,000 hectares by 2030.
- In June 2020, hemp acreage reached about 190,000 hectares for the 47 state departments that declared agricultural numbers, representing a decline of 9% on 2019’s figures.
- 95% of the hemp that is harvested within the US is destined for cannabinoid production according to industry operators.
In collaboration with:
Download our reports
The Pharmaceutical Cannabis Report
The rapid growth of cannabis-based medicines is becoming a significant disruptor of the global pharmaceutical industry, but the point of entry has been complicated by the historic scheduling of cannabis as a schedule 1 narcotic. However, pharmaceutical cannabis products such as Epidyolex, Sativex and Dronabinol have become serious alternatives to traditional pharmaceuticals and are beginning to shift how the pharma industry approaches cannabis.
Clinical trials and academic studies are on the rise, constantly changing our understanding of the cannabis plant. In tandem, commercial opportunities are emerging as innovation, capital and technology create a space for a new form of cannabis-based medicines, which will change the way we medicate over the next 5-10 years. We utilise our vast global network and experience to unpack the regulatory landscape across key markets, analyse the key trends which are changing the face of the market and examine the businesses and technologies that are set to disrupt the industry.
For as little as £650, we provide 75 pages of market research, competitor analysis and consumer data that will ensure you future-proof your business and maximise growth in this rapidly changing sector.
The Pharmaceutical Cannabis Report examines:
- Prohibition Partners estimates that worldwide sales for pharmaceutical cannabinoid therapeutics will total almost US$800 million in 2020.
- Epidiolex® remains the leading pharmaceutical cannabis products. In the US, it enjoyed sales of over US$116.1 million in Q1 2020 and US$117.7 million in Q2 2020.
- Existing pharmaceutical cannabis products will achieve growth rates of 150% between 2020 and 2024 to reach total value sales just shy of US$2 billion.
The Consumer
Our consumer insights, detailed analysis and market intelligence allow you to determine the best strategies surrounding the pharmaceutical cannabis market. Take advantage of reliable expert data to help inform your businesses strategies.
The Competitors
Who are the big pharmaceutical companies driving growth and development in the pharmaceutical sector? Our team look at the latest company and brand activity allowing you to analyse the market and stay ahead of the competition.
The Market
Our five-year forecasts breakdown the latest market sizing, market growth and buying behaviours to forecast growth projections. Our industry-leading data allows you to attract investment by confidently projecting growth within the market.
The Innovations
Stay ahead of your competitors. Understand the role technology is playing in the rapidly growing pharmaceutical market. Understand how and why new product formats are entering the market, adapting to patients needs and requirements as they are developed.
The Opportunities
Our consultants and analysts will help you to identify the most relevant opportunities with the pharmaceutical market. Which regions and emerging opportunities are the best and how can your business take advantage?
The Trends
What are the latest trends emerging in the pharmaceutical cannabis industry? Our trends analysis allow you to understand what is shaping the market and how you can stay at the forefront.
Download our reports
CBD: The Consumer Report
CBD has become one of the biggest disruptors of mainstream industries over the last decade, impacting sectors from pharma to food and wellness to cosmetics. Already a multibillion dollar opportunity globally, the market is expanding at an unprecedented rate but many small-scale operators, multinational FMCGs and investors are struggling to understand the attitudes and spending that will dictate the future of this rapidly burgeoning market.
In order to examine this rapidly-moving market, our industry-leading consultants and analysts provide unparalleled proprietary consumer data from over 15,000 adults across seven key markets to help you to understand the current and future profile of the CBD consumer. We utilise our vast global network and experience to unpack the regulatory landscape across key markets, analyse the key trends which are changing the face of the market and examine the brands and businesses that are set to disrupt the industry.
For as little as £450, we provide 160 pages of market research, competitor analysis and consumer data that will ensure you future-proof your business and maximise growth in this rapidly volatile market.
CBD: The Consumer Report examines:
- At 52%, the majority of consumers are using CBD to help with sleep and relaxation while 51% of consumers are using CBD to manage health & wellness and to treat various health conditions.
- Nearly 30% of users in mature markets such as the US and Canada expect to increase their usage of CBD during the global pandemic, primarily to deal with stress, anxiety and to manage wellness.
- The OTC CBD market is expected to be worth US$5.8 billion in 2020 with the potential to grow by 16% over the review period to US$6.79 billion.
The Consumer
Use our consumer insights, detailed analysis and market intelligence to help inform strategies for your CBD business. Use reliable expert data to help you to deliver effective marketing and product strategies across your business.
The Competitors
Who is at the forefront of the market, who is driving change and disruption in the CBD sector? Our consumer data allows you to evaluate the competition so you become a market expert.
The Market
Our five-year forecasts present the latest market sizes and analyse consumer buying behaviour, spending and patterns to determine growth projections. Utilise our industry-leading data and projections to help secure investment, attract business partners and drive growth.
The Innovations
Stay ahead of the competition. Understand how the technology in the CBD space is changing the market. Discover how new formats are coming to market and how they’re adapting to consumers needs and requirements.
The Opportunities
Our consultants and analysts identify the most exciting opportunities within the CBD market. Where are the emerging opportunities and geographic and how can your business take advantage?
The Trends
Keep up to date with the newest and most exciting trends which are emerging in the CBD market. Our trends analysis helps you to understand how and why the market is shifting.
Download our reports
The Impact Series: Disrupting Food
Cannabis is becoming the most disruptive force in the global food market for decades, impacting everything from confectionery to fine-dining. Multinational FMCG firms and a new demographic of cannabis consumer are entering the market as countries from every corner of the globe loosen regulations.
The global cannabis and CBD food market is set to be worth $6.6 billion by 2024. However, as the market opens up businesses are faced with a lack of consumer data, market intelligence and regulatory clarity. THE IMPACT SERIES: Disrupting Food analyses exclusive consumer data from over 15,000 adults across seven international markets and breaks down rapidly shifting regulations, helping businesses, brands and investors to understand the the future of the market.
Find out how and why consumers are buying, what regulations are defining the market and how the major industry leaders are approaching the industry over 150+ pages of data, intelligence and insight from experts in the field.
The Impact Series: Disrupting Food examines:
- Exclusive proprietary research and consumer polling across 15,000 respondents.
- Financial market forecasting and industry growth expectations from 2020 to 2024.
- Explore the brands driving change, innovation and market disruption.
The Consumer
See detailed analysis and breakdowns of consumers, what makes them use and purchase cannabis & CBD food products? Tailor your product offering and marketing to achieve the most impact.
The Competitors
Find out who are the leaders in the market and who to watch out for. Use data and intelligence to find out who your competitors are and the challenges they may be facing.
The Market
Our five-year forecasts will help inform your strategy for investment in the cannabis edibles market. Harness data and intelligence to understand what is driving growth in the market.
The Innovations
Discover new food products launching in the cannabis & CBD space, and understand the motivations and trends which are pushing the market forwards and answering consumers demands.
The Opportunities
Zoom in on the key opportunities for your business or brand and strategise on how you can nurture them. Use our data and intelligence to connect with consumers and markets.
The Trends
Identify the latest trends developing in the cannabis edibles market. Our trends analysis will deepen your understanding of the ways in which culture, legislation and key developments influence consumer behaviour and consumption.
Download our reports
The Impact Series: Disrupting Drinks
Cannabis is becoming the most disruptive force in the trillion-dollar global beverages market in decades, impacting non-alcoholic and alcoholic sectors. Disrupting Drinks is the first in our series of in-depth consumer research reports, offering a comprehensive deep dive into the emerging cannabis drinks market, supporting businesses, investors and regulators in one of the most exciting sectors in the industry.
Our unique consumer research polls over 26,000 adults across nine country markets in three continents (North America, Europe and Asia) on their usage, purchase and attitudes towards cannabinoid-based products. The report aims to help you to understand the key consumer profiles, market trends and commercial opportunities in one of the fastest-growing segments in the global cannabis market.
The Impact Series: Disrupting Drinks examines:
- Consumer research across 15,000 respondents.
- Profiling of 9,000 potential users.
- Market value forecasts and growth from 2020 to 2024.
- Deep dives into key brands, innovators and market entrants.
The Consumer
Know your consumer and your potential consumers. Who are they and what are their motivations for use and purchase? Tailor your product offering, marketing and messaging for maximum effect.
The Competitors
Get the low down on the key players in the market and the ones to watch. Learn about niche innovation that has the opportunity to go mainstream. Identify your competitors, and potential partners.
The Market
Plan your strategy based on our 5 year forecasts. Understand what is driving market value and growth and which geographies offer you the greatest opportunities.
The Innovations
Learn about new product launches for a deeper understanding of trends that are driving the market and tapping into consumer requirements.
The Opportunities
Identify new opportunities for your business or brand. From the most receptive consumer profile, to the most welcoming geography, our report will ensure your strategy is well-informed.
The Trends
Take a look at consumer trends shaping the development of the market. Our trends analysis helps you to understand how culture, recent events and legislation influence consumer demand and consumption.
Download our reports
The Oceania Cannabis Report: Second Edition
The Oceania Cannabis Report: Second Edition is the most extensive review of the cannabis industry in Australia, New Zealand and surrounding islands. The report provides detailed market value forecasts and offers in-depth analysis of the countries and companies that are operating at the cutting edge of the industry.
The Oceania Cannabis Report: Second Edition examines:
In collaboration with:
Download now
PSYCH: The Psychedelics as Medicine Report
Medical psychedelics are rapidly disrupting the way we view modern healthcare. Once the darling of the medical community, medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation. PSYCH: The Psychedelics as Medicine Report presents unparalleled insights and intelligence into this emerging movement, helping to guide investors, operators and regulators through this transient phase. Download your free copy now.
PSYCH: The Psychedelics as Medicine Report examines:
In collaboration with:
Download now
The European Cannabis Report 5th Edition
The landscape of the European cannabis industry is shifting as quickly as the legislation that underpins it. The European Cannabis Report: 5th Edition, revisits the landscape of cannabis in Europe, providing insights into the latest developments across the continent, and delivering intelligence across key markets such as France, Portugal, Germany, Italy, Spain and the UK. The report helps unpack complex legislation and key data for international policymakers and industry-leading operators.
The European Cannabis Report 5th Edition examines:
• Comprehensive analysis of European cannabis legislation
• Proprietary market forecasts for key cannabis markets
• An overview of commercial opportunities across multiple industry sectors
In collaboration with:
Download our reports
The Impact Series: Disrupting Beauty
Prohibition Partners is proud to present Disrupting Beauty, the first report in our 'Impact Series’ showcasing how cannabis is permeating the mainstream. Disrupting Beauty documents how cannabis is disrupting the traditional beauty market and the supply chain as demand skyrockets for cannabis beauty products.
The Impact Series: Disrupting Beauty examines:
• The brands and businesses driving the cannabis beauty market
• Market forecasts for the cannabis beauty industry
• Key regulations and legislation dictating the sector
Download our reports
The UK Cannabis Report
The UK Cannabis Report delivers a comprehensive and complete analysis of the UK cannabis sector, providing expert commentary on the newly published NICE Guidelines and breakdowns of the latest developments across the sector. The report features the latest data from a market which is expected to be worth US$4.3 billion by 2024. Download the full report to access industry-leading research and expert opinions covering healthcare, commercial activity and investment trends in the UK market.
The UK Cannabis Report examines:
In collaboration with:
Download our reports
The New Normal Report
Prohibition Partners is proud to present The New Normal Report, in collaboration with Protein Agency. The report documents the rise of CBD and the permeation of cannabis into the mainstream, exploring the brands and businesses that are driving growth across beauty, sport, lifestyle and food and drink sectors. The report takes a deep-dive into consumer trends and examines how brands can connect with the emerging cannabis consumer. Download for free now.
The New Normal Report examines:
Download our reports
The Global Cannabis Report
The landscape of the global cannabis industry is shifting as quickly as the legislation that underpins it. The Prohibition Partners' The Global Cannabis Report, an industry first of its kind, analyses the key developments across the global cannabis sector and provides proprietary market forecasts across the continental markets: Africa, Asia, Europe, Latin America, North America and Oceania. The report predicts that the international cannabis market could be worth up to US$103.9 billion by 2024, and outlines key commercial opportunities for international operators and investors.
The Global Cannabis Report examines:
In collaboration with:
Download our reports
The Poland Cannabis White Paper
Poland is expected to play a central role in the European cannabis market in the coming years, after becoming the 12th country to legalise medicinal cannabis on the continent in 2017. With the Polish market expected to be worth at least €2 billion by 2028, key opportunities will be available to investors, entrepreneurs and influencers in the near future.
The Poland Cannabis White Paper examines:
Download our reports
The Germany Cannabis Report
The Germany Cannabis Report is the first and only free-to-access report to focus on the biggest economy in Europe and its burgeoning cannabis market. Having legalised medical cannabis in 2017 and achieved a market value of over €73 million in 2018, Germany is set to play a central role in the European market in the coming years, which is estimated to be worth over €123 billion by 2028.
The Germany Cannabis Report examines:
In collaboration with:
Download our reports
The North American Cannabis Report
The North American Cannabis Report is the first and only free-to-access report on the cannabis industry in the United States and Canada, a market worth a potential $47.3 billion by 2024. Although the US is currently the most profitable cannabis industry in the world, the lack of legislative clarity at the federal level is disrupting the industry. Canada has taken a leadership position at the international level, having legalised recreational cannabis in October 2018. The market is set to grow at an unprecedented rate over the next five years, as legislation shifts in favour of liberalisation and consumer industries begin to move in on the cannabis space.
The North American Cannabis Report examines:
In collaboration with:
Download our reports
The Cannabis Legal Report™
Prohibition Partners’ inaugural The Cannabis Legal Report™ provides the most comprehensive review of the legislation and regulation governing the emerging legal cannabis market. Attitudes towards medical cannabis are shifting amongst the public, and policymakers, professionals and investors are beginning to take note. This report runs through the crucial insights needed to understand the burgeoning cannabis market which could be worth an estimated €123 billion by 2028 in Europe alone.
The Cannabis Legal Report™ examines:
In collaboration with:
Download our reports
The European Cannabis Report™ 4th Edition
Home to more than 740 million people, a population more than double that of the United States and Canada combined, Europe is set to become the world’s largest legal cannabis market over the next five years. In the last 12 months alone, the European cannabis industry has grown more than in the last six years. Six countries have announced new legislation and over €500million has been invested in European cannabis businesses and as our exclusive research shows, Europe’s cannabis market is estimated to be worth up to €123 billion by 2028.
The European Cannabis Report™ 4th Edition examines:
In collaboration with:
Download our reports
The Asian Cannabis Report™
Asia, the world’s most populous continent, has a relatively low prevalence of cannabis use at just 2% annually. However, this is the equivalent to an estimated 85.5 million people, making Asia a key market in the long-term expansion plans of producers, investors and operators. As the historically conservative stance on cannabis begins to soften, the medical market alone could be worth as much as US$5.8 billion by 2024.
The Asian Cannabis Report™ examines:
In collaboration with:
Download our reports
The African Cannabis Report™
While cannabis remains illegal in most African countries, many nations are keen to embrace cultivation as a way to boost their economies. Cannabis is already widely grown and consumed across the continent with production currently standing at around 38,000 tonnes and consumption rates at 13.2%. While any path towards a legalised and regulated cannabis industry presents a number of significant challenges due to opaque laws and inconsistent enforcement, Africa’s climate, affordable land and low-cost labour offer enormous opportunities in a market that could exceed $US7.1 billion by 2023.
The African Cannabis Report™ examines:
In collaboration with:
Download our reports
Medical Cannabis in Europe – The GMP Standards Guide
Prohibition Partners is excited to announce the launch of 'Medical Cannabis in Europe - The GMP Standards Guide', in association with Orion GMP Solutions. As European legislators start to develop and implement national cannabis programmes using EU Good Manufacturing Practice guidelines, we examine how these requirements impact the cultivation, importation and distribution of medical cannabis within the EU.
In collaboration with:
Download our reports
The Oceania Cannabis Report™
Australia legalised medical cannabis in October 2016. Two years later, they aim to become one of the global leaders in the legal cannabis industry establishing themselves as major players in the cultivation, manufacturing and distribution industries.
The Oceania Cannabis Report™ examines:
In collaboration with:
Download our reports
The LATAM Cannabis Report™
The LATAM market is expected to grow rapidly over the next 10 years. The region is quickly introducing some of the most relaxed legislation on legal cannabis in the world, in a bid to become a global leader in medical cannabis cultivation.
The LATAM Cannabis Report™ examines:
In collaboration with:
Download our reports
The European Cannabis Report™
Regulatory changes, public support and evidence of cannabis’ therapeutic effects are driving growth in the European cannabis industry. The market itself has the potential to be worth €115 billion but the size of Europe’s opportunity is counterbalanced by the scale of complexity in navigating each country’s unique legal framework.
The European Cannabis Report™ examines:
In collaboration with:
